Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: Current state of art and future perspectives

Blood

Volumn 121, Issue 11, 2013, Pages 1944-1950

  Young, Guy ^a   Sørensen, Benny ^b,c,d   Dargaud, Yesim ^e   Negrier, Claude ^e   Brummel Ziedins, Kathleen ^f   Key, Nigel S ^g  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITÉ LYON 1   (France)

^f UNIVERSITY OF VERMONT   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING; BLOOD EXAMINATION; BLOOD VISCOSITY; HEMOPHILIA; HUMAN; LABORATORY TEST; MULTICENTER STUDY (TOPIC); PHENOTYPE; PRIORITY JOURNAL; REVIEW; STANDARDIZATION; THROMBIN GENERATION MEASUREMENTS; THROMBIN TIME; THROMBOELASTOGRAPHY; THROMBOELASTOMETRY; BLOOD; BLOOD CLOTTING TEST; EVALUATION; HEMATOLOGY; HEMOPHILIA A; MALE; METABOLISM; METHODOLOGY; PHYSIOLOGY; PROGNOSIS; STANDARD;

THROMBIN;

BLOOD COAGULATION TESTS; BLOOD VISCOSITY; HEMATOLOGY; HEMOPHILIA A; HUMANS; MALE; PROGNOSIS; REFERENCE STANDARDS; THROMBIN;

MLCS; MLOWN;

EID: 84877607719     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-08-378935     Document Type: Review

References (33)

1. Amby LK, Seremetis S, Obergfell A, et al. Challenges of defining reliable clinical surrogate end points in haemophilia trials: a critical review. Blood Coagul Fibrinolysis. 2009;20(7):488-493.
2. Quick AJ, Stanley-Brown M, Bancroft FW. A study of the coagulation defect in hemophilia and in jaundice. Am J Med Sci. 1935;190(4):501-510.
3. Brummel KE, Paradis SG, Butenas S, et al. Thrombin functions during tissue factor-induced blood coagulation. Blood. 2002;100(1):148-152.
4. Aledort LM, Haschmeyer RH, Pettersson H; The Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. J Intern Med. 1994; 236(4):391-399.
5. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33(1):4-15.
6. Sorensen B, Young G. Global laboratory assays in hemophilia. In: Lee C, Berntorp E, Hoots K, eds. Textbook of Hemophilia, 2nd ed. Oxford, UK: Wiley-Blackwell; 2010:263-268.
7. Dargaud Y, Béguin S, Lienhart A, et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost. 2005;93(3):475-480.
8. Santagostino E, Mancuso ME, Tripodi A, et al. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost. 2010;8(4):737-743.
9. Trossaert M, Regnault V, Sigaud M, et al. Mild hemophilia A with factor VIII assay discrepancy: potential utility of thrombin generation assays. J Thromb Haemost. 2008;6(3):486-493.
10. Dargaud Y, Lienhart A, Meunier S, et al. Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision. Haemophilia. 2005;11(5):552-558.
11. Dargaud Y, Lienhart A, Negrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood. 2010;116(25):5734-5737.
12. Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia. 2009; 15(1):3-10.
13. Barrowcliffe TW. Monitoring inhibitor patients with the right assays. Semin Hematol. 2008; 45(2 Suppl 1):S25-S30.
14. Beltrán-Miranda CP, Khan A, Jaloma-Cruz AR, et al. Thrombin generation and phenotypic correlation in haemophilia A. Haemophilia. 2005; 11(4):326-334.
15. Hartert H. Blutgerinnungsstudien mit der Thrombelastographie; einem neuen Untersuchungs verfahren. Klin Wochenschr. 1948;26(37-38):577-583.
16. Calatzis A, Fritsche P, Calatzis A, et al. A comparison of the technical principle of the roTEG coagulation analyzer and conventional thrombelastographic systems. Ann Hematol. 1996;72(suppl 1):90. [abstract]
17. Salooja N, Perry DJ. Thrombelastography. Blood Coagul Fibrinolysis. 2001;12(5):327-337.
18. Sørensen B, Johansen P, Christiansen K, et al. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost. 2003;1(3): 551-558.
19. Sorensen B, Ingerslev J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost. 2004;2(1):102-110.
20. Young G, Blain R, Nakagawa P, et al. Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia. 2006;12(6): 598-604.
21. Brummel-Ziedins KE, Whelihan MF, Gissel M, et al. Thrombin generation and bleeding in haemophilia A. Haemophilia. 2009;15(5): 1118-1125.
22. Rea CJ, Foley JH, Ingerslev J, et al. Factor XIII combined with recombinant factor VIIa: a new means of treating severe hemophilia A. J Thromb Haemost. 2011;9(3):510-516.
23. Hvas AM, Sorensen HT, Norengaard L, et al. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe haemophilia A. J. Thromb Haemost. 2007;5(12):2408-2412.
24. Chitlur M, Warrier I, Rajpurkar M, et al. Thromboelastography in children with coagulation factor deficiencies. Br J Haematol. 2008;142(2): 250-256.
25. Sørensen B, Persson E, Ingerslev J. Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A. Br J Haematol. 2007;137(2):158-165.
26. Sørensen B, Ingerslev J. Platelet infusion supports recombinant factor VIIa in a patient with severe haemophilia A and inhibitor—clinical outcome and laboratory observations. Thromb Haemost. 2010;103(6):1275-1276.
27. Dargaud Y, Wolberg AS, Luddington R, et al. Evaluation of a standardized protocol for thrombin generation measurement using the calibrated automated thrombogram: an international multicentre study. Thromb Res. 2012;130(6): 929-934. [Epub ahead of print].
28. Favaloro EJ. Internal quality control and external quality assurance of platelet function tests. Semin Thromb Hemost. 2009;35(2):139-149.
29. Parhami-Seren B, Butenas S, Krudysz-Amblo J, et al. Immunologic quantitation of tissue factors. J Thromb Haemost. 2006;4(8):1747-1755.
30. Young G, Ebbesen LS, Viuff D, et al. Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicenter trial. Blood Coag Fibrin. 2008;19(4):276-282.
31. Young G, Zhang R, Miller R, et al. Comparison of kaolin and tissue factor activated thromboelastography in haemophilia. Haemophilia. 2010;16(3):518-524.
32. Viuff D, Andersen S, Sørensen BB, et al. Optimizing thrombelastography (TEG) assay conditions to monitor rFVIIa (NovoSeven) therapy in haemophilia A patients. Thromb Res. 2010; 126(2):144-149.
33. Gissel M, Whelihan MF, Ferris LA, et al. The influence of prophylactic factor VIII in severe haemophilia A. Haemophilia. 2012;18(2):193-199.